```
=> d que 157
L1        25646 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "B CELL (LYMPHOCYTE)"+OLD,NT/C
                T
L2          585 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "B CELL (LYMPHOCYTE) (L)
                DISEASE"+OLD/CT
L3        89634 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "T CELL (LYMPHOCYTE)"+OLD,NT/C
                T
L4         2317 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "T CELL (LYMPHOCYTE) (L)
                DISEASE"+OLD/CT
L5        11390 SEA FILE=HCAPLUS ABB=ON  PLU=ON  MAST CELL+OLD,NT/CT
L6         1116 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "LYMPHOCYTE (L) PLASMA
                CELL"+OLD/CT
L7         6586 SEA FILE=HCAPLUS ABB=ON  PLU=ON  MULTIPLE MYELOMA+OLD/CT
L8           98 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "LEUKEMIA (L) PLASMA CELL"/CT

L9        17792 SEA FILE=HCAPLUS ABB=ON  PLU=ON  MYELOID
L10      231677 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ANTIBODIES+OLD,NT/CT
L11         922 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "DRUG DELIVERY SYSTEMS (L)
                IMMUNOCONJUGATES"+OLD/CT
L12      167382 SEA FILE=HCAPLUS ABB=ON  PLU=ON  CYTOKINES+OLD,NT/CT
L13       10258 SEA FILE=HCAPLUS ABB=ON  PLU=ON  IMMUNOTHERAPY+OLD,NT/CT
L14          25 SEA FILE=HCAPLUS ABB=ON  PLU=ON  NAKED(3A)ANTIBOD?
L15       14807 SEA FILE=HCAPLUS ABB=ON  PLU=ON  RIBONUCLEASE/CT
L16      138591 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L1 OR L2 OR L3 OR L4 OR L5
                OR L6 OR L7 OR L8 OR L9)
L20         974 SEA FILE=HCAPLUS ABB=ON  PLU=ON  DOMESTIC ANIMAL+OLD/CT
L21       10768 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "DOG (CANIS FAMILIARIS)"+OLD,N
                T/CT
L22        4942 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CAT (FELIS CATUS)"+OLD,NT/CT

L23         865 SEA FILE=HCAPLUS ABB=ON  PLU=ON  FELIDAE+OLD/CT
L24        9287 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "HORSE (EQUUS CABALLUS)"+OLD,N
                T/CT
L25       23476 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23 OR
                L24)
L27        7507 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD4 (ANTIGEN)"+OLD,NT/CT
L28         861 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD5 (ANTIGEN)"+OLD/CT
L29        3780 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD8 (ANTIGEN)"+OLD/CT
L30        1764 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD14 (ANTIGEN)"+OLD,NT/CT
L31         266 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "ANTIGENS (L) SSEA-1 (STAGE-SP
                ECIFIC EMBRYONIC ANTIGEN 1)"+OLD/CT
L32         978 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "BLOOD-GROUP SUBSTANCES (L)
                LEX"/CT
L33         899 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD19 (ANTIGEN)"+OLD/CT
L34         727 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD20 (ANTIGEN)"+OLD/CT
L35         620 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "COMPLEMENT RECEPTORS (L)
                TYPE 2"+OLD/CT
L36         435 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD22 (ANTIGEN)"+OLD/CT
L37        6932 SEA FILE=HCAPLUS ABB=ON  PLU=ON  INTERLEUKIN 2 RECEPTORS+OLD/CT

L38        1585 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "INTERLEUKIN 2 RECEPTORS (L)
                .ALPHA.-CHAIN"+OLD/CT
L39         380 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD ANTIGENS (L) CD33"+OLD/CT

L40         689 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD38 (ANTIGEN)"+OLD/CT
L41         126 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CD ANTIGENS (L) CD52"+OLD/CT
```

```
L42        8115 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CELL ADHESION MOLECULES (L)
                ICAM-1 (INTERCELLULAR ADHESION MOL. 1)"+OLD/CT
L43        3349 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "INVARIANT CHAIN (CLASS II
                ANTIGEN)"+OLD,NT/CT
L44         202 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "GENE, ANIMAL (L) MUC1"/CT
L45        1432 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "HISTOCOMPATIBILITY ANTIGENS
                (L) IA (H-2 I-REGION-ASSOCD.)"+OLD/CT
L46        4952 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "HISTOCOMPATIBILITY ANTIGENS
                (L) HLA-DR"+OLD/CT
L47        3383 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L27 OR L28 OR L29 OR L30 OR
                L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR
                L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46)(L)ANTIBOD?
L48      395439 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L10 OR L14 OR L11 OR L12 OR
                L15 OR L47
L49       59807 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L16 AND L48
L50        2263 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L49 AND L13
L51      125881 SEA FILE=HCAPLUS ABB=ON  PLU=ON  NEOPLASM+OLD/CT
L52      162735 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ANTITUMOR AGENTS+OLD/CT
L53      273065 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 OR L52
L54        1102 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L50 AND L53
L55          11 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L54 AND L25
L56          20 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L16 AND L48 AND L13 AND L25
L57          20 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L55 OR L56

=> d l57 ibib ab hitind 1-20

L57  ANSWER 1 OF 20  HCAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2003:719500  HCAPLUS
DOCUMENT NUMBER:          139:244702
TITLE:                    Anti-protozoal vaccines comprising immunogenic
                          fragments of hypoxanthine guanine xanthine
                          phosphoribosyl transferase and B cell epitopes
INVENTOR(S):              Makobongo, Morris; Riding, George Alfred; Willadsen,
                          Peter; Good, Michael
PATENT ASSIGNEE(S):       The Council of the Queensland Institute of Medical
                          Research, Australia
SOURCE:                   PCT Int. Appl., 66 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO 2003074543      A1   20030912      WO 2003-AU246    20030228
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
```

NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2002-845 A 20020301

AB Immunotherapy of protozoal diseases is provided by use of hypoxanthine guanine xanthine phosphoribosyl transferase protein, or peptide fragments thereof, as an immunogen in vaccines effective against protozoal diseases such as malaria and babesiasis. In particular, immunization with hypoxanthine guanine xanthine phosphoribosyl transferase or peptide fragments thereof, induces T cell immunity to blood stage malaria. In particular embodiments, the invention provides protein and DNA malaria vaccines and methods of prophylactic and therapeutic immunization that elicit T cell-mediated immune responses broadly applicable to protozoal diseases including malaria.

IC ICM C07H021-02
ICS C07H021-04; C12N005-06; C12N005-08; C07K014-445; C07K014-44; C07K016-20; A61K031-7105; A61K031-711; A61K038-10; A61K038-45; A61K039-015; A61K039-018; A61P033-06

CC 15-2 (Immunochemistry)
Section cross-reference(s): 63

IT **B cell (lymphocyte)**
T cell (lymphocyte)
(epitope; immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

IT Anaplasma
Animal
Babesia
Babesia bigemina
Babesia bovis
Babesia canis
Babesia divergens
Babesia microtia
CD4-positive T cell
Cattle
Chicken (Gallus domesticus)
Coccidiosis
DNA sequences
Dog (Canis familiaris)
Eimeria tenella
Epitopes
Giardia lamblia
Human
Immunotherapy
Leishmania braziliensis
Leishmania donovani
Leishmania mexicana
Leishmania tropica
Mammalia
Mouse
Plasmodium (malarial genus)
Plasmodium berghei yoelii
Protein sequences
Protozoa
Toxoplasma gondii
Trypanosoma congolense
Trypanosoma cruzi
Trypanosoma gambiense

Vaccines
(immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

IT **Cytokines**
Interleukin 2
Tumor necrosis factors
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

IT **Interferons**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(.gamma.; immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:656808 HCAPLUS
DOCUMENT NUMBER: 139:196278
TITLE: Anti-CD20 antibodies and fusion proteins for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases
INVENTOR(S): Hansen, Hans; Qu, Zhengxing; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; McCall, John Douglas
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068821	A2	20030821	WO 2003-GB665	20030214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,

ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2002-356132P P 20020214
US 2002-416232P P 20021007

AB The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.

IC ICM C07K016-28
ICS A61K039-395; C12N015-13; C12N005-10; G01N033-53

CC 15-3 (Immunochemistry)
Section cross-reference(s): 1, 3, 8, 9, 63

IT **Interleukins**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(21; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antigens**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD126; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **CD antigens**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**CD33**; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **CD antigens**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**CD52**; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(G1; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(G; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Histocompatibility antigens**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**HLA-DR**; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antigens**

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HM1.24; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Cell adhesion molecules**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**ICAM-1** (**intercellular adhesion mol. 1**); humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Histocompatibility antigens**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**Ia** (**H-2 I-region-assocd.**); humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antigens**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**SSEA-1** (**stage-specific embryonic antigen 1**); humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bispecific; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **B cell (lymphocyte)**
(**disease**; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell **disease**, B cell malignancy and autoimmune diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chains; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell

malignancy and autoimmune diseases)

IT Alkylating agents, biological
Angiogenesis inhibitors
Antibiotics
Autoimmune disease
B cell (lymphocyte)
Biomarkers (biological responses)
Cat (Felis catus)
Color formers
Cytotoxic agents
DNA sequences
Dog (Canis familiaris)
Domestic animal
Drug delivery systems
Drugs
Dyes
Epitopes
Genetic vectors
Human
Imaging agents
Immunomodulators
Immunotherapy
Labels
Lymphocyte
Lymphoma
Mammalia
Molecular cloning
Mouse
Multiple myeloma
Myasthenia gravis
Protein sequences
Pseudomonas
Rodentia
Transplant rejection
cDNA sequences
(humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of **B cell disease, B cell** malignancy and autoimmune diseases)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Abrins
Alkaloids, biological studies
Anthracyclines
Antisense oligonucleotides
CD14 (antigen)
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)

CD5 (antigen)
CD8 (antigen)
CD80 (antigen)
CD80 (antigen)
Cytokines
Enzymes, biological studies
Fusion proteins (chimeric proteins)
Hemopoietins
Hormones, animal, biological studies
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 3
Interleukin 6
Interleukins
Invariant chain (class II antigen)
Lymphotoxin
Oligonucleotides
Radionuclides, biological studies
Ricins
Stem cell factor
Tenascins
Toxins
Transforming proteins
Tumor necrosis factors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Drug delivery systems**
(**immunoconjugates**; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chains; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell

malignancy and autoimmune diseases)

IT **Complement receptors**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**type 2**; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Interleukin 2 receptors**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**.alpha.-chain**; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Interferons**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Interferons**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Interferons**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma.; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT 55-86-7, Nitrogen mustard 57-13-6D, Urea, substituted derivs. 59-30-3D, Folic acid, analogs 60-34-4D, Methylhydrazine, derivs. 120-73-0D, Purine, analogs 151-56-4D, Ethylenimine, derivs. 289-95-2D, Pyrimidine, analogs 1605-68-1D, Taxane, analogs 4375-07-9D, Epipodophyllotoxin, derivs. 7439-89-6, Iron, biological studies 7439-96-5, Manganese, biological studies 7440-06-4D, Platinum, coordination complexes 7440-54-2, Gadolinium, biological studies 7689-03-4D, Camptothecin, analogs **9001-99-4**, Ribonuclease 9003-98-9, DNase I 9014-42-0, Thrombopoietin 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 11096-26-7, Erythropoietin 13010-20-3D, Nitrosourea, derivs. 13981-22-1, Nitrogen-13, biological studies 13981-56-1, Fluorine-18, biological studies 13982-43-9, Oxygen-15, biological studies 14119-09-6, Gallium-67, biological studies 14158-30-6, Iodine-124, biological studies 14158-31-7, Iodine-125, biological studies 14265-75-9, Lutetium-177, biological studies 14265-85-1, Actinium-225, biological studies 14276-53-0, Copper-62, biological studies 14333-33-6, Carbon-11, biological studies 14378-26-8, Rhenium-188, biological studies 14391-73-2, Copper-66, biological studies 14596-37-3, Phosphorus-32, biological studies 14809-53-1, Yttrium-86, biological studies 14913-49-6, Bismuth-212, biological studies 14998-63-1, Rhenium-186, biological studies 15056-34-5D, Triazene, derivs. 15715-08-9, Iodine-123, biological studies 15750-15-9, Indium-111, biological studies 15755-39-2, Astatine-211, biological studies 15757-14-9, Gallium-68, biological studies 15757-86-5, Copper-67, biological studies 15765-38-5, Bromine-76, biological studies

15776-20-2, Bismuth-213, biological studies 23214-92-8D, Doxorubicin, analogs 33069-62-4D, Taxol, analogs 62683-29-8, Colony stimulating factor 75037-46-6, Gelonin 83869-56-1, GM-CSF 127464-60-2, Vascular endothelial growth factor 143011-72-7, G-CSF 187888-07-9D, Endostatin, analogs 352423-07-5, Placenta growth factor 378784-41-9, Technetium-94m, biological studies 378784-45-3, Technetium-99m, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

L57 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:488616 HCAPLUS
DOCUMENT NUMBER: 139:67777
TITLE: Generation of genetically modified vertebrate precursor lymphocytes for production of antibody, antigen receptor, heterologous binding protein or fragment
INVENTOR(S): Grawunder, Ulf; Melchers, Georg Friedrich
PATENT ASSIGNEE(S): Germany
SOURCE: Eur. Pat. Appl., 111 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1321477	A1	20030625	EP 2001-130805	20011222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003068819	A1	20030821	WO 2001-EP15303	20011222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2001-130805 A 20011222

AB The present invention generally relates to the fields of genetic engineering and antibody prodn. In particular, it relates to the generation of genetically modified vertebrate precursor lymphocytes that have the potential to differentiate into more mature lymphoid lineage cells, and to the use thereof for the prodn. of any heterologous antibody or binding protein. Retroviral vector pLIB-bcl2-IRES-hygroB was constructed for overexpression of Bcl2 gene in murine. Long term proliferating murine precursor B cells with inactivated endogenous Ig. heavy and light chain gene loci were prepd. and used to generate human Ig.-producing murine precursor B cells.

IC ICM C07K016-00
ICS C12N005-20; C12N005-10; C12N005-06; A61K039-00

CC 15-3 (Immunochemistry)
Section cross-reference(s): 3, 9

IT **Cytokines**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(TNFSF7 (tumor necrosis factor superfamily member 7); generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bispecific; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT Amphibia
Aves
B cell (lymphocyte)
Bacteria (Eubacteria)
Bony fish (Osteichthyes)
Cattle
Chondrichthyes
Chromosome
DNA sequences
Gene targeting
Genetic markers
Genetic vectors
Gram-negative bacteria
Guinea pig (Cavia porcellus)
Horse (Equus caballus)
Human
Hybridoma
Immunization
Immunotherapy
Lymphocyte
Mammalia
Mitogens
Molecular cloning
Mouse
Multiple myeloma
Plasmids
Rabbit
Rat

Reptilia
Retroviral vectors
Rodentia
Sheep
Swine
T cell (lymphocyte)
Transplant and Transplantation
Vertebrata
Viral vectors
Yeast
(generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT Antigen receptors
Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **CD19 (antigen)**
CD20 (antigen)
CD30 (antigen)
CD38 (antigen)
CD40 (antigen)
CD80 (antigen)
CD86 (antigen)
Fas antigen
Genetic element
Growth factors, animal
Interleukin 10
Interleukin 13
Interleukin 2
Interleukin 4
Interleukin 5
Interleukin 6
LFA-3 (antigen)
Lipopolysaccharides
Lipoproteins
Promoter (genetic element)
TCR (T cell receptors)
Transferrin receptors
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(generation of genetically modified vertebrate precursor lymphocytes for prodn. of **antibody**, antigen receptor, heterologous binding protein or fragment)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); REM (Removal or disposal); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(heavy chains; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **T cell (lymphocyte)**
(helper cell, antigen-primed; generation of genetically modified

vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterologous; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); REM (Removal or disposal); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(light chains; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multiple specific; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Complement receptors**
Tumor necrosis factor receptors
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**type 2**; generation of genetically modified vertebrate precursor lymphocytes for prodn. of **antibody**, antigen receptor, heterologous binding protein or fragment)

IT **Interferons**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(.gamma.; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:454152 HCAPLUS
DOCUMENT NUMBER: 139:51593
TITLE: Allergens, autoantigens and their T cell epitopes for

inducing immune tolerance and for immunotherapy
INVENTOR(S): Larche, Mark; Ledger, Philip William
PATENT ASSIGNEE(S): Circassia Limited, UK
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047618	A2	20030612	WO 2002-GB5548	20021205

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-338385P P 20011205

AB Methods for desensitizing an individual to a selected polypeptide antigen are provided. The methods entail administration of T cell epitope contg. peptides from a polypeptide antigen in such a way as to establish a tolergeneic environment, i.e., a state of hyporesponsiveness to the peptides. The selected polypeptide antigen is then administered such that the state of hyporesponsiveness and co-administration of the selected antigen are sufficient to desensitize the individual to the polypeptide antigen. Also provided are therapeutic systems useful in the methods of the invention, and the use of polypeptide antigens and peptides in the manuf. of medicaments in the methods of the invention.

IC ICM A61K039-35
CC 15-2 (Immunochemistry)
Section cross-reference(s): 63
IT Blattaria
Calliphoridae
Cat (Felis catus)
Cattle
Chironomidae
Coleoptera
Dermatophagoides
Diptera
Dog (Canis familiaris)
Embryophyta
Food
Fungi
Gerbil
Guinea pig (Cavia porcellus)
Honeybee
Horse (Equus caballus)
Housefly (Musca domestica)
Larva
Latex

Mammalia
Mite and Tick
Mold (fungus)
Mouse
Poaceae
Pollen
Rabbit
Ragweed (Ambrosia)
Rat
Sheep
Silkworm
Spider
Swine
Tenebrio molitor
Tephritidae
Tree
Wasp
(allergen; allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)

IT Allergy
Autoimmune disease
Behcet's syndrome
Celiac disease
Epitopes
Immunotherapy
Multiple sclerosis
Myasthenia gravis
Protein sequences
Rheumatoid arthritis
Transplant and Transplantation
(allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)

IT **Immunotherapy**
(desensitization; allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)

IT **T cell (lymphocyte)**
(epitopes; allergen; allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)

IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heavy chains; allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)

L57 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:316762 HCAPLUS
DOCUMENT NUMBER: 138:352624
TITLE: Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy
AUTHOR(S): Itoh, Hiroshi; Kakuta, Tomoko; Kudo, Tetsuya; Sakonju, Iwao; Hohdatsu, Tsutomu; Ebina, Takusaburo; Takase, Katsuaki
CORPORATE SOURCE: Department of Veterinary Surgery, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, 034-8628, Japan
SOURCE: Journal of Veterinary Medical Science (2003), 65(3),

329-333
CODEN: JVMSEQ; ISSN: 0916-7250
PUBLISHER: Japanese Society of Veterinary Science
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Interleukin (IL)-2 can induce large nos. of lymphokine-activated killer cells in peripheral blood lymphocytes (PBL), but IL-2 alone cannot induce proliferation of a large no. of canine (c) PBL. We used the solid phase anti-CD3 antibody and sol. recombinant (r) IL-2 in order to establish a large scale culture method for cPBL. The no. of lymphocytes seeded (3 .times. 107) increased to 1 .times. 109 after incubation for 10 days. The phenotype of cultured cPBL cells (after 2 wk) showed a CD4+ or CD8+ predominant cell population. The cultured cell solns. were administered with physiol. saline i.v. to each dog. After transfusion of the cultured cells, the cPBL counts, esp. the no. of CD4+, CD8+ and CD4-CD8-(DN) cells increased significantly in the recipient dogs. Natural killer (NK) cells, .gamma..vdelta.T cells and B cells were considered to be present in the DN cell population. The NK cells and .gamma..vdelta.T cells showed no adverse reaction to the transfusion of the activated cPBL. Therefore, it is necessary to recognize the B cells present in the DN cell population by detecting CD21+ cells. In conclusion, the bulk culture system of cPBL with rIL-2 and solid phase anti-CD3 antibody may be useful for the development of novel immunotherapy in dogs.

CC 15-8 (Immunochemistry)

IT **CD4-positive T cell**
CD8-positive T cell
Dog (Canis familiaris)
Immunotherapy
Lymphocyte
(bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy)

IT **Interleukin 2**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy)

IT **Antibodies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(to CD3; bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:223756 HCAPLUS
DOCUMENT NUMBER: 138:253705
TITLE: Immunostimulatory peptide compounds for prevention and the treatment of mammalian diseases
INVENTOR(S): Papierok, Gerard; Vicens, Serge
PATENT ASSIGNEE(S): Fr.
SOURCE: Fr. Demande, 45 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2829767	A1	20030321	FR 2001-11942	20010914
WO 2003025012	A2	20030327	WO 2002-FR3134	20020913

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2001-11942 A 20010914

AB The invention discloses peptide compds. for the prevention or treatment of diseases in mammals, in particular humans, canines, felines, and equines, whose protective immunity depends on the stimulation of Th1 lymphocytes, and in particular delayed hypersensitivity. The peptide compds. comprise the sequences AARCARCREGYSITDE or AASSTPSPGSGCEVDG or derivs. thereof. The peptide compds. may be used in the prodn. of medicaments, vaccines, and diagnostic reagents.

IC ICM C07K007-08
ICS C07K014-44; G01N033-68; G01N033-531; A61K038-10; A61K039-008; A61P037-02

CC 15-2 (Immunochemistry)
Section cross-reference(s): 1, 9

IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(G2; immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT **T cell (lymphocyte)**
(helper cell/inducer, TH1; immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT **T cell (lymphocyte)**
(helper cell/inducer, TH2; immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT Canidae
Dog (Canis familiaris)
Drug delivery systems
Equidae
Felidae
Human
Immobilization, molecular
Immunostimulants
Leishmania donovani infantum
Test kits
Vaccines
(immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT **Antibodies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT Chemotherapy
Immunotherapy
(treatment efficacy; immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:977608 HCAPLUS
DOCUMENT NUMBER: 138:54553
TITLE: Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma
INVENTOR(S): An, Ling-Ling; Wu, Herren; Fung, Michael S. C.
PATENT ASSIGNEE(S): Tanox, Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102320	A2	20021227	WO 2002-US19448	20020614

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-298710P P 20010615
AB The present invention includes Fc.epsilon. fragments conjugated with FC.gamma. fragments, for example, Fc.epsilon.1-Hinge-Fc.epsilon.2-Fc.epsilon.3-Fc.epsilon.4-Fc.gamma.; Hinge-Fc.epsilon.2-Fc.epsilon.3-Fc.epsilon.4-Fc.gamma.; Fc.epsilon.2-Fc.epsilon.3-Fc.epsilon.4-Fc.gamma.; Fc.epsilon.2-Fc.epsilon.3-Fc.gamma.; Fc.epsilon.3-Fc.gamma.; and Fc.epsilon.3-Fc.epsilon.4-Fc.gamma., or any deriv. or peptide, which has equiv. immunol. function. The Fc.gamma. fragment may be a fragment of any of the IgG subclasses (IgG1, IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds Fc.gamma.RIIB. The present invention also includes compns. suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical compn. including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.
IC ICM A61K
CC 15-9 (Immunochemistry)
Section cross-reference(s): 17
IT **Immunoglobulins**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E, Fc.epsilon. fragment, fusion protein with Fc.gamma.; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and

asthma)
IT Allergy
Asthma
Basophil
Cat (Felis catus)
Dog (Canis familiaris)
Drug allergy
Food allergy
Genetic vectors
Hay fever
Human
Immunotherapy
Mast cell
Protein engineering
(Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)
IT **Immunoglobulins**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(G, Fc.gamma. fragment, fusion protein with Fc.epsilon.; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)
IT **Immunoglobulins**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(G1, Fc.gamma. fragment, fusion protein with Fc.epsilon.; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)
IT **Immunoglobulins**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(G3, Fc.gamma. fragment, fusion protein with Fc.epsilon.; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)
IT **Antibodies**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-IgE; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)

L57 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:716299 HCAPLUS
DOCUMENT NUMBER: 137:246549
TITLE: Immunoglobulin fusion proteins that target low-affinity Fc.gamma. receptors
INVENTOR(S): Arnason, Barry G. W.; Jensen, Mark A.; White, David M.
PATENT ASSIGNEE(S): University of Chicago, USA
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072608	A2	20020919	WO 2002-US7365	20020311

WO 2002072608 A3 20030508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003161826 A1 20030828 US 2002-96521 20020311
PRIORITY APPLN. INFO.: US 2001-274392P P 20010309

AB The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc.gamma.R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc.gamma.R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the Fc region of human IgG1. Convenient restriction sites allow for the facile introduction of addnl. N-terminal domains. In one example, the extracellular domain of human CD8.alpha. was fused with 0-4 HCH2 segments and the Fc region of IgG1. The fusion protein was shown to stimulate proliferation of interleukin-2-primed natural killer cells.

IC ICM C07K
CC 15-3 (Immunochemistry)
IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)
IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)
IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)
IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(G1, Fc region fusion products; with hinge-CH2 multimers and other proteins)
IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(G2; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)
IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(G3; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)
IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(G4; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)
IT **Immunoglobulins**

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(M; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)

IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fragments, hinge-CH2 region fusion products; with IgG Fc domain and other proteins)

IT **B cell (lymphocyte)**
Macrophage
Monocyte
T cell (lymphocyte)
(fusion proteins targeting Fc receptors of)

IT Allergy inhibitors
Anti-inflammatory agents
Antiasthmatics
Antibacterial agents
Antirheumatic agents
Antitumor agents
Antiviral agents
Fungicides
Immunotherapy
Protozoacides
(fusion proteins targeting Fc.gamma. receptors)

IT **Cat (Felis catus)**
Cattle
Dog (Canis familiaris)
Goat
Horse (Equus caballus)
Human
Mouse
Rodentia
Sheep
Swine
(fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of Igs of)

IT **Antibodies**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized, fusion products; targeting to Fc.gamma. receptors of)

IT **Interferons**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma.; expression by NK cells activated by fusion protein targeting Fc.gamma.RIII receptors)

L57 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:676339 HCAPLUS
DOCUMENT NUMBER: 137:210942
TITLE: Use of immunostimulatory CpG island-containing nucleic acids for treatment of diseases
INVENTOR(S): Schetter, Christian; Vollmer, Jorg
PATENT ASSIGNEE(S): Coley Pharmaceutical Group, Ltd., Bermuda
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069369	A2	20020906	WO 2001-IB2888	20011210
WO 2002069369	A3	20030626		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1350262	A2	20031008	EP 2001-273824	20011210
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003181406	A1	20030925	US 2002-140013	20020506

PRIORITY APPLN. INFO.: US 2000-254341P P 20001208
WO 2001-IB2888 W 20011210

OTHER SOURCE(S): MARPAT 137:210942

AB Immunostimulatory compns. described as CpG-like nucleic acids are provided, including nucleic acids having immunostimulatory characteristics of CpG nucleic acid, despite certain substitutions of C, G, or C and G of the CpG dinucleotide. The substitutions can include, among others, exchange of methylated C for C, inosine for G, and ZpY for CpG, where Z is Cytosine or dSpacer and Y is inosine, 2-aminopurine, nebularine, or dSpacer. Also provided are methods for inducing an immune response in a subject using the CpG-like nucleic acids. The methods are useful in the treatment of a subject that has or is at risk of developing an infectious disease, allergy, asthma, cancer, anemia, thrombocytopenia, or neutropenia.

IC ICM H01L

CC 1-7 (Pharmacology)
Section cross-reference(s): 15, 63

IT **Antitumor agents**
(CpG islands as; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)

IT **B cell (lymphocyte)**
Monocyte
Mononuclear cell (leukocyte)
(CpG nucleic acids in stimulation of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)

IT **Cytokines**
Interleukin 1
Interleukin 12
Interleukin 18
Interleukin 1.beta.
Interleukin 2
Interleukin 3
Interleukin 4
Interleukin 6
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(immunostimulatory nucleic acids in induction of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of

diseases)
IT **Antibodies**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, as anti-tumor agents; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
IT **T cell (lymphocyte)**
(natural killer, stimulating activity of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
IT Allergy inhibitors
Anti-infective agents
Antiasthmatics
Antibacterial agents
Antimicrobial agents
Antiulcer agents
Antiviral agents
Cat (Felis catus)
Cattle
Chemotherapy
Chicken (Gallus domesticus)
Dog (Canis familiaris)
Drug delivery systems
Fish
Fungicides
Goat
Guinea pig (Cavia porcellus)
Horse (Equus caballus)
Human
Immunity
Immunostimulants
Immunotherapy
Infection
Neoplasm
Nonhuman primate
Parasiticides
Rabbit
Sheep
Swine
Ulcer
(use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
IT **Antitumor agents**
(vaccines; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
IT **Interferons**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha., immunostimulatory nucleic acids in induction of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
IT **Interferons**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma., immunostimulatory nucleic acids in induction of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)

L57 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:615861 HCAPLUS

DOCUMENT NUMBER: 137:168289
TITLE: Use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy
INVENTOR(S): Buchanan, Bob B.; Del Val, Gregorio; Frick, Oscar L.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002063012	A2	20020815	WO 2002-US3346	20020204
WO 2002063012	A3	20030313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003170763	A1	20030911	US 2002-67484	20020204
US 2003180225	A1	20030925	US 2002-67620	20020204

PRIORITY APPLN. INFO.: US 2001-266686P P 20010205

AB A 30 kDa ragweed complete pollen ext. disulfide protein allergen has been purified from ragweed pollen, discarded in the com. defatting process of pollen. This protein is glycosylated, is water sol. and has at least one disulfide bond. IgE immunoblots with sera of ragweed sensitive patients indicated that the 30 kDa protein is a major allergen. The 30 kDa protein finds use in allergy testing and immunotherapy regimens. In addn. to the 30 kDa disulfide protein isolated from complete ragweed pollen, an 8-10 kDa ragweed complete pollen ext. disulfide protein and a 30 kDa ragweed defatted pollen ext. disulfide protein and fragments, derivs. and homologues thereof are described.

IC ICM C12N015-29
ICS C07K014-415; C07K016-16; A61K039-36

CC 15-9 (Immunochemistry)
Section cross-reference(s): 6, 11

IT **Immunoglobulins**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(E, Ambt7 pollen allergen binding to; use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

IT **Dog (Canis familiaris)**
(as disease model, for allergy; use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

IT **B cell (lymphocyte)**
T cell (lymphocyte)
(epitope of Ambt7 pollen allergen; use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

IT **Antibodies**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical

study); BIOL (Biological study); USES (Uses)
(monoclonal, to ragweed Ambt7 pollen allergen; use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

IT **Antibodies**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(to ragweed Ambt7 pollen allergen; use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

IT Human
Immunotherapy
Mammalia
Pollen
Ragweed (Ambrosia)
(use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

L57 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:314731 HCAPLUS
DOCUMENT NUMBER: 136:324056
TITLE: Fusion cells and cytokine compositions for treatment of disease
INVENTOR(S): Ohno, Tsuneya
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032378	A2	20020425	WO 2001-US47057	20011022
WO 2002032378	A3	20030227		
WO 2002032378	C2	20030626		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002168351	A1	20021114	US 2001-12134	20011022

PRIORITY APPLN. INFO.: US 2000-242154P P 20001020

AB The present invention relates to methods and compns. for treating and preventing cancer and infectious disease by administering a therapeutically ED of fusion cells formed by fusion of autologous dendritic cells and autologous non-dendritic cells, in combination with a cytokine or other mol. which stimulates or induces a cytotoxic T cell response and/or a humoral immune response. The examples discuss cancer vaccines comprising interleukin 12 and dendritic cells fused with tumor cells which induce tumor-specific cytotoxic T-cells. The dendritic cells act as antigen-presenting cells for the tumor-assocd. antigens, thereby inducing tumor-specific immune responses.

IC ICM A61K

CC 15-2 (Immunochemistry)
IT **Antitumor agents**
(Ewing's sarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(Kaposi's sarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(Wilms' tumor; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(acoustic neuroma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(acute lymphocytic leukemia; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(acute myelogenous leukemia; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(adenocarcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(astrocytoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(basal cell carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(bile duct carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(bladder carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(brain; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(bronchi carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(cervix; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(chondrosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(chordoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(choriocarcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(colon carcinoma; dendritic/non-dendritic fusion cells and cytokines

for treatment of cancer and infection)

IT **Antitumor agents**
(craniopharyngioma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(cystadenocarcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **T cell (lymphocyte)**
(cytotoxic; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT Adenoviridae
Adoptive immunotherapy
Antigen presentation
Antitumor agents
Arbovirus
CD4-positive T cell
CD8-positive T cell
Cat (Felis catus)
Cattle
Cytolysis
Cytomegalovirus
Dog (Canis familiaris)
Fusion, biological
Goat
Hamster
Hepatitis A virus
Hepatitis B virus
Herpesviridae
Horse (Equus caballus)
Human
Human T-lymphotropic virus 1
Human T-lymphotropic virus 2
Human coxsackievirus
Human herpesvirus 4
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Infection
Influenza virus
Measles virus
Monocyte
Mouse
Papovaviridae
Parvovirus
Picornaviridae
Polycythemia vera
Polyomavirus
Poultry
Poxviridae
Rabies virus
Rat
Reoviridae
Rhinovirus
Rubella virus
Semliki Forest virus
Sendai virus
Sheep
Simian virus 40

Swine
Togaviridae
Vaccines
Vaccinia virus
(dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Cytokines**
Interleukin 12
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(embryonal carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(ependymoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(fibrosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Neoplasm**
Neuroglia, neoplasm
(fusion with dendritic cell; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(glioma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(hemangioblastoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(hemangiosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
Antitumor agents
(hepatoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(leiomyosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(leukemia, chronic; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(leukemia; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(liposarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(lung carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(lung small-cell carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**

(lymphangioendotheliosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(lymphangiosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(lymphoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(mammary gland; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(medullary carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(medulloblastoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(melanoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(meningioma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(mesothelioma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(multiple myeloma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(myxosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(neuroblastoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(oligodendroglioma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(osteosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(ovary; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(pancreas; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(pinealoma inhibitors; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(prostate gland; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**
(renal cell carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**

(retinoblastoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(rhabdomyosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(sebaceous gland carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(seminoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(squamous cell carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(sweat gland; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(synovial membrane tumor inhibitors; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(testis; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(thyroid adenocarcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(thyroid gland papillary carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
IT **Antitumor agents**
(vaccines; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

L57 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:276421 HCAPLUS
DOCUMENT NUMBER: 136:278150
TITLE: Immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins
INVENTOR(S): Goldenberg, David M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,134,982.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002041847	A1	20020411	US 2001-921290	20010803
US 6306393	B1	20011023	US 1999-307816	19990510

PRIORITY APPLN. INFO.: US 1998-38995 A2 19980312
US 1999-307816 A2 19990510
US 1997-41506P P 19970324

AB B-cell, T-cell, **myeloid**-cell, mast-cell, and plasma-cell disorders are significant contributors to illness and mortality in domestic animals, esp. in companion animals such as dogs and cats. These disorders include both autoimmune disorders and malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma, acute and chronic lymphocytic or **myeloid** leukemias, multiple myeloma, and mastocytomas. Antibody components that bind with B-cell or T-cell antigens or epitopes, as well as antigens or epitopes of **myeloid**, plasma and mast cells provide an effective means to treat these disorders in domestic animals. The immunotherapy uses **naked antibodies**, immunoconjugates and fusion proteins, alone or in combination with std. therapeutic regimens.

IC ICM A61K039-395
ICS A61K051-00

NCL 424001490

CC 15-3 (Immunochemistry)
Section cross-reference(s): 1, 8

ST immunotherapy autoimmune disease cancer antibody lymphocyte antigen; mast cell antigen antibody immunotherapy autoimmune disease cancer; **myeloid** cell antigen antibody immunotherapy autoimmune disease cancer

IT **Antitumor agents**
(B-cell lymphoma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD126; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **CD antigens**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**CD33**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **CD antigens**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**CD52**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Histocompatibility antigens**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**HLA-DR**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HM1.24; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Cell adhesion molecules**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**ICAM-1** (**intercellular adhesion mol. 1**); immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Histocompatibility antigens**

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**Ia** (**H-2 I-region-assocd.**); immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MHC (major histocompatibility complex), class II; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antigens**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**SSEA-1** (**stage-specific embryonic antigen 1**); immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT Lymphoproliferative disorders
(Waldenstrom's macroglobulinemia; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antitumor agents**
(acute lymphocytic leukemia; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Antitumor agents**
(acute myelogenous leukemia; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT Fusion proteins (chimeric proteins)
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibody-contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT Anemia (disease)
(autoimmune hemolytic anemia; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Antibodies**
RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(bispecific; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antitumor agents**
(chronic lymphocytic leukemia; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antitumor agents**

(chronic myelocytic leukemia; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT Dyes
(conjugates with antibody; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT Carboranes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(conjugates with antibody; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT Radionuclides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with antibody; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT Drugs
(immunoconjugate contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Cytokines**
Toxins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunoconjugate contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Drug delivery systems**
(**immunoconjugates,** antibody-contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies, immunoconjugates** and fusion proteins)

IT **Antitumor agents**
Autoimmune disease
B cell (lymphocyte)
Cat (Felis catus)
Chemotherapy
Diagnosis
Dog (Canis familiaris)
Epitopes
Horse (Equus caballus)
Immunomodulators
Immunosuppressants
Immunotherapy
Mast cell
Radiotherapy
T cell (lymphocyte)
(immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antibodies**
RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(immunotherapy of malignant and autoimmune disorders in domestic

animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT Antigens
CD14 (antigen)
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD38 (antigen)
CD4 (antigen)
CD5 (antigen)
CD8 (antigen)
Haptens
Interleukin 2 receptors
Invariant chain (class II antigen)
RL: BSU (Biological study, unclassified); BIOL (Biological study) (immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antitumor agents**
(lymphoma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Mast cell**
(mastocytoma, inhibitors; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies** , immunoconjugates and fusion proteins)

IT **Antitumor agents**
(mastocytoma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antibodies**
RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antitumor agents**
(multiple myeloma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antibodies**
RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(multispecific; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT Hematopoietic precursor cell
(**myeloid;** immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies,** immunoconjugates and fusion proteins)

IT **Antitumor agents**
(non-Hodgkin's lymphoma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies** , immunoconjugates and fusion proteins)

IT Chemicals

(photoactive, conjugates with antibody; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Lymphocyte**
(**plasma cell**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **Complement receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**type 2**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT **9001-99-4**, RNase
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunoconjugate contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

IT 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 57-22-7, Vincristine
10043-66-0D, I 131, labeled immunoconjugate, biological studies
10098-91-6D, Y 90, labeled immunoconjugate, biological studies
23214-92-8, Doxorubicin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

L57 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:123216 HCAPLUS
DOCUMENT NUMBER: 136:182466
TITLE: Anti-tumor necrosis factor antibodies for diagnosing and treating obesity, immune disease, cancer, infections and others
INVENTOR(S): Giles-Komar, Jill; Knight, David M.; Heavner, George; Scallon, Bernard; Shealy, David
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012502	A2	20020214	WO 2001-US24785	20010807
WO 2002012502	A3	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003049725	A1	20030313	US 2001-920137	20010801
AU 2001079227	A5	20020218	AU 2001-79227	20010807
EP 1309691	A2	20030514	EP 2001-957489	20010807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013110	A	20030916	BR 2001-13110	20010807
NO 2003000620	A	20030331	NO 2003-620	20030207

PRIORITY APPLN. INFO.:

US 2000-223360P	P	20000807
US 2000-236826P	P	20000929
US 2001-920137	A	20010801
WO 2001-US24785	W	20010807

AB The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compns., methods and devices. The antibodies may combined with other drugs such as TNF antagonist, antirheumatic, muscle relaxant, narcotic, NSAID, analgesic, anesthetic, sedative, etc. and used for treating obesity, immunol.diseases, infectious diseases, cancers and others.

IC ICM C12N015-13
ICS C07K016-24; C12N015-79; C12N005-10; A61K039-395; C07K016-42; G01N033-50; G01N033-577; A61P037-00

CC 15-3 (Immunochemistry)
Section cross-reference(s): 1, 2, 3, 8, 9, 63

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(G1; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(G; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT Amphibia
Analgesics
Anesthetics
Animal cell
Animal tissue
Antiasthmatics
Antidepressants
Antimicrobial agents
Antipsychotics
Antirheumatic agents
Antitumor agents
Autoimmune disease
Cardiovascular system, disease
DNA sequences
Epitopes
Eukaryota
Fish
Genetic vectors
Goat
Hamster
HeLa cell

Hormone replacement therapy
Horse (Equus caballus)
Human
Hypnotics and Sedatives
Immunosuppressants
Immunotherapy
Infection
Inflammation
Insecta
Labels
Medical goods
Molecular cloning
Mouse
Muscle relaxants
Narcotics
Nervous system, disease
Nervous system stimulants
Neuromuscular blocking agents
Obesity
Organ, animal
Plant cell
Primates
Prokaryote
Protein sequences
Rabbit
Radiopharmaceuticals
Rat
Reptilia
Rodentia
Sheep
(anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Antibodies**
Immunoglobulins
Nucleic acids
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Cytokines**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-idiotypic; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT Lymphoma
Multiple myeloma
(cells; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chains; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chains; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Antitumor agents**
Neoplasm
(metastasis; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

L57 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:123215 HCAPLUS
DOCUMENT NUMBER: 136:182465
TITLE: Anti-.alpha.V.beta.3/.alpha.V.beta.5 dual integrin antibodies for diagnosis and therapeutic uses
INVENTOR(S): Giles-Komar, Jill; Heavner, George; Snyder, Linda; Trikha, Mohit
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012501	A2	20020214	WO 2001-US24784	20010807
WO 2002012501	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003040044	A1	20030227	US 2001-920267	20010801
AU 2001083167	A5	20020218	AU 2001-83167	20010807

EP 1309693 A2 20030514 EP 2001-961945 20010807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
NO 2003000621 A 20030401 NO 2003-621 20030207
PRIORITY APPLN. INFO.: US 2000-223363P P 20000807
US 2001-920267 A 20010801
WO 2001-US24784 W 20010807

AB The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compns., methods and devices. The dual integrins are .alpha.V.beta.3 and .alpha.V.beta.5. The antibodies are esp. useful for diagnosis and treatment of .alpha.V.beta.3/.alpha.V.beta.5-assocd. diseases such as (but not limited to) obesity, immunol. diseases, cardiovascular diseases, infectious diseases, malignant diseases, or neurol. diseases.

IC ICM C12N015-13
ICS C07K016-28; C12N015-79; C12N005-10; A61K039-395; C07K016-42; G01N033-50; G01N033-577; A61P037-00

CC 15-3 (Immunochemistry)
Section cross-reference(s): 1, 2, 3, 8, 9, 63

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(G1; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(G; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-idiotypic; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT Amphibia
Analgesics
Anesthetics
Animal cell
Animal tissue
Antiasthmatics
Antidepressants
Antimicrobial agents
Antipsychotics
Antirheumatic agents
Antitumor agents
Autoimmune disease
Cardiovascular system, disease
DNA sequences
Epitopes
Eukaryota
Fish

Genetic vectors
Goat
HeLa cell
Hormone replacement therapy
Horse (Equus caballus)
Human
Hypnotics and Sedatives
Immunosuppressants
Immunotherapy
Infection
Inflammation
Insecta
Labels
Medical goods
Molecular cloning
Mouse
Muscle relaxants
Narcotics
Nervous system, disease
Nervous system stimulants
Neuromuscular blocking agents
Obesity
Organ, animal
Plant cell
Primates
Prokaryote
Protein sequences
Rabbit
Radiopharmaceuticals
Rat
Reptilia
Rodentia
Sheep
(anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Antibodies**
Immunoglobulins
Nucleic acids
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Cytokines**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT Lymphoma
Multiple myeloma
(cells; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for

diagnosing and treating immunol. diseases and infection and cancer)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chains; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Immunoglobulins**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chains; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Antitumor agents**
Neoplasm
(metastasis; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

L57 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:636194 HCAPLUS
DOCUMENT NUMBER: 135:194468
TITLE: Hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy
INVENTOR(S): Kanz, Lothar; Walden, Peter; Stuhler, Gernot
PATENT ASSIGNEE(S): Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum, Germany
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062902	A1	20010830	WO 2000-EP2433	20000320
W: AE, AG, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, MA, MD, MG, MN, MW, MX, NO, NZ, PL, RU, SD, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10009030	A1	20010920	DE 2000-10009030	20000227
EP 1130088	A1	20010905	EP 2000-105829	20000320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003524020	T2	20030812	JP 2001-562676	20000320

PRIORITY APPLN. INFO.: DE 2000-10009030 A 20000227
US 2000-185334P P 20000228

WO 2000-EP2433 W 20000320

AB The present invention relates to methods and compns. for treating and preventing cancer and infectious disease using hybrid cells formed by fusion of allogeneic dendritic cells and autologous non-dendritic cells which shares at least one class I MHC (major histocompatibility complex) allele. Such hybrid cells combine the vigorous alloreactivity of mature dendritic cells with the specific antigenicity of autologous tumor cells, thereby eliciting a highly specific and vigorous cytotoxic T lymphocytes (CTL) response. The invention also provides the methods for making hybrid cell vaccines and evaluating its cytotoxicity. For rapid and large-scale generation of hybrids, electrofusion is established as a two-step procedure: in the first step, tumor cells and dendritic cells (DCs) were dielectrophoretically aligned to from cell-cell conjugates; in the second step, a fusion pulse was applied, yielding 10-15% hybrid cell formation. The invention demonstrates that vaccine with tumor cell-dendritic cell hybrid results in regression of human metastatic renal cell carcinoma.

IC ICM C12N005-16
ICS C12N005-22; A61K039-00

CC 15-2 (Immunochemistry)
Section cross-reference(s): 1

IT **Antitumor agents**
(Ewing's sarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(Kaposi's sarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(Waldenstroem's macroglobulinemia; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(Wilms' tumor; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(acoustic neuroma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(acute lymphocytic leukemia; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(acute myelogenous leukemia; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(adenocarcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(astrocytoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**

(basal cell carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(bile duct carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(bladder carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(bronchi carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(cervix; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(chondrosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(chordoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(choriocarcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(colon carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(craniopharyngioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(cystadenocarcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **T cell (lymphocyte)**
(cytotoxic; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(ependymoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(fibrosarcoma; hybrid cell vaccines derived by fusion of an allogeneic

dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(glioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Immunoglobulins**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heavy chains, disease, treatment of; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(hemangiosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(hepatoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT Antibacterial agents
Antiviral agents
Cat (Felis catus)
Cattle
Cell fusion
Dog (Canis familiaris)
Goat
Hamster
Horse (Equus caballus)
Immunotherapy
Mouse
Parasiticides
Poultry
Protozoacides
Rat
Sheep
Swine
Test kits
Transformation, genetic
(hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(leiomyosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(leukemia; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(liposarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(lung carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(lung small-cell carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(lymphangiosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(lymphoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(mammary gland; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(medulloblastoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(melanoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(meningioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(mesothelioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(multiple myeloma, treatment of; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(myosarcoma inhibitors; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(neuroblastoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(oligodendroglioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(osteosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(ovary; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**

(pancreas; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(pinealoma inhibitors; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(prostate gland; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(renal cell carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(retinoblastoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(rhabdomyosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(sebaceous gland carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(seminoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(squamous cell carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(sweat gland; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(synovial membrane tumor inhibitors; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(testis; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(thyroid gland carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT **Antitumor agents**
(thyroid gland papillary carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

IT Anti-AIDS agents
Antitumor agents

(vaccines; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:617775 HCAPLUS
DOCUMENT NUMBER: 135:194459
TITLE: Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
INVENTOR(S): Belldegrun, Arie; Tso, Cho-Lea
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060317	A2	20010823	WO 2001-US4595	20010213
WO 2001060317	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001036967	A5	20010827	AU 2001-36967	20010213
US 2002058041	A1	20020516	US 2001-783708	20010213
EP 1255554	A2	20021113	EP 2001-909186	20010213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-182429P P 20000214
US 2000-182636P P 20000215
WO 2001-US4595 W 20010213

AB This invention provides an anti-cancer immunogenic agent(s) e.g. vaccine(s) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric mol. comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.

IC ICM A61K
CC 15-2 (Immunochemistry)
Section cross-reference(s): 63
IT **T cell (lymphocyte)**
(cytotoxic; kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)
IT **Cytokines**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunomodulatory; kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)

IT **Adoptive immunotherapy**
Antigen-presenting cell
Antitumor agents
B cell (lymphocyte)
Blood cell
Canidae
Cat (Felis catus)
Cattle
DNA sequences
Dendritic cell
Epitopes
Eukaryote (Eukaryotae)
Fibroblast
Genetic vectors
Horse (Equus caballus)
Kidney, neoplasm
Lagomorpha
Lymphocyte
Mammal (Mammalia)
Molecular cloning
Monocyte
Muscle
Nonhuman primate
Protein sequences
Rodent
Swine
T cell (lymphocyte)
Virus vectors
(kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)

IT **Neoplasm**
(metastasis, cell; kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)

IT **Antitumor agents**
(vaccines; kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)

L57 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:247187 HCAPLUS
DOCUMENT NUMBER: 134:275762
TITLE: Immunostimulatory nucleic acids
INVENTOR(S): Krieg, Arthur M.; Schetter, Christian; Vollmer, Jorg
PATENT ASSIGNEE(S): University of Iowa Research Foundation, USA; Coley Pharmaceutical G.b.m.H.
SOURCE: PCT Int. Appl., 338 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022972	A2	20010405	WO 2000-US26383	20000925
WO 2001022972	A3	20020117		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1221955	A2	20020717	EP 2000-965433	20000925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014236	A	20021015	BR 2000-14236	20000925
JP 2003510282	T2	20030318	JP 2001-526182	20000925
EE 200200158	A	20030616	EE 2002-158	20000925
ZA 2002001963	A	20030310	ZA 2002-1963	20020308
BG 106538	A	20021229	BG 2002-106538	20020321
NO 2002001453	A	20020527	NO 2002-1453	20020322

PRIORITY APPLN. INFO.:	US 1999-156113P	P	19990925
	US 1999-156135P	P	19990927
	US 2000-227436P	P	20000823
	WO 2000-US26383	W	20000925

OTHER SOURCE(S): MARPAT 134:275762

AB The invention relates to immunostimulatory nucleic acid compns. and methods of using the compns. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/or greater than 50% C nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids contg. CpG motifs. The invention also encompasses preferred CpG nucleic acids.

IC ICM A61K031-7088
ICS A61K039-39; A61K048-00; A61K035-12; A23L001-30; A61P037-04; A61K031-7088; A61K031-00; A61K031-7088; A61K038-00; A61K031-7088; A61K039-395

CC 1-7 (Pharmacology)
Section cross-reference(s): 15, 63

IT **Antitumor agents**
(Hodgkin's disease inhibitors; immunostimulatory nucleic acids)

IT **Antitumor agents**
(biliary tract; immunostimulatory nucleic acids)

IT **Antitumor agents**
(bone; immunostimulatory nucleic acids)

IT **Antitumor agents**
(brain; immunostimulatory nucleic acids)

IT **Antitumor agents**
(carcinoma; immunostimulatory nucleic acids)

IT **Antitumor agents**
(central nervous system; immunostimulatory nucleic acids)

IT **Antitumor agents**
(cervix; immunostimulatory nucleic acids)

IT **Antitumor agents**
(choriocarcinoma; immunostimulatory nucleic acids)

IT **Antitumor agents**
(colon; immunostimulatory nucleic acids)

IT **Antitumor agents**
(connective tissue tumor inhibitors; immunostimulatory nucleic acids)

IT **Antitumor agents**
(endometrium; immunostimulatory nucleic acids)
IT **Antitumor agents**
(esophagus; immunostimulatory nucleic acids)
IT **Antitumor agents**
(eye; immunostimulatory nucleic acids)
IT **Antitumor agents**
(hepatoma; immunostimulatory nucleic acids)
IT Allergy inhibitors
Anti-infective agents
Antiasthmatics
Antibacterial agents
Antimicrobial agents
Antitumor agents
Antiviral agents
B cell (lymphocyte)
Campylobacter
Cat (Felis catus)
Cattle
Cell proliferation
Chemotherapy
Chicken (Gallus domesticus)
Clostridium
Dendritic cell
Dog (Canis familiaris)
Drug delivery systems
Endosome
Escherichia coli
Fish
Fungicides
Genetic vectors
Goat
Haemophilus
Herpesviridae
Horse (Equus caballus)
Immunostimulants
Immunotherapy
Leukocyte
Monkey
Monocyte
Mononuclear cell (leukocyte)
Orthomyxoviridae
Parasiticides
Retroviridae
Sheep
Staphylococcus
Swine
Toxoplasma
(immunostimulatory nucleic acids)
IT **Antibodies**
Antigens
Oligonucleotides
Phosphorothioate oligonucleotides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunostimulatory nucleic acids)

IT **Interleukin 12**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(immunostimulatory nucleic acids)
IT **Interleukin 6**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(immunostimulatory nucleic acids)
IT **Antitumor agents**
(intraepithelial cancer; immunostimulatory nucleic acids)
IT **Antitumor agents**
(kidney; immunostimulatory nucleic acids)
IT **Antitumor agents**
(larynx tumor inhibitors; immunostimulatory nucleic acids)
IT **Antitumor agents**
(lung non-small-cell carcinoma; immunostimulatory nucleic acids)
IT **Antitumor agents**
(lung small-cell carcinoma; immunostimulatory nucleic acids)
IT **Antitumor agents**
(lung; immunostimulatory nucleic acids)
IT **Antitumor agents**
(lymphoma; immunostimulatory nucleic acids)
IT **Antitumor agents**
(mammary gland; immunostimulatory nucleic acids)
IT **Antitumor agents**
(melanoma; immunostimulatory nucleic acids)
IT **Antitumor agents**
(mouth, and oral cavity; immunostimulatory nucleic acids)
IT **T cell (lymphocyte)**
(natural killer; immunostimulatory nucleic acids)
IT **Antitumor agents**
(neuroblastoma; immunostimulatory nucleic acids)
IT **Antitumor agents**
(ovary; immunostimulatory nucleic acids)
IT **Antitumor agents**
(pancreas; immunostimulatory nucleic acids)
IT **B cell (lymphocyte)**
(proliferation; immunostimulatory nucleic acids)
IT **Antitumor agents**
(prostate gland; immunostimulatory nucleic acids)
IT **Antitumor agents**
(rectum; immunostimulatory nucleic acids)
IT **Antitumor agents**
(sarcoma; immunostimulatory nucleic acids)
IT **Antitumor agents**
(skin; immunostimulatory nucleic acids)
IT **Antitumor agents**
(stomach; immunostimulatory nucleic acids)
IT **Antitumor agents**
(testis; immunostimulatory nucleic acids)
IT **Antitumor agents**
(thyroid; immunostimulatory nucleic acids)
IT **Antitumor agents**
(vaccines; immunostimulatory nucleic acids)
IT **Interferons**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(.gamma.; immunostimulatory nucleic acids)

L57 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:672376 HCAPLUS
DOCUMENT NUMBER: 129:270609
TITLE: Modified TALL-104 cells to treat cancer
INVENTOR(S): Santoli, Daniela; Rovera, Giovanni; Cesano, Alessandra
PATENT ASSIGNEE(S): The Wistar Institute of Anatomy and Biology, USA
SOURCE: U.S., 30 pp., Cont.-in-part of U.S. Ser. No. 63,188, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5820856	A	19981013	US 1995-446814	19951208
US 5272082	A	19931221	US 1992-859927	19920330
CA 2162732	AA	19941124	CA 1994-2162732	19940512
WO 9426284	A1	19941124	WO 1994-US5374	19940512
W: AU, CA, JP, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9469126	A1	19941212	AU 1994-69126	19940512
AU 694430	B2	19980723		
EP 697875	A1	19960228	EP 1994-917384	19940512
EP 697875	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08510131	T2	19961029	JP 1994-525736	19940512
AT 211915	E	20020215	AT 1994-917384	19940512
ES 2171169	T3	20020901	ES 1994-917384	19940512

PRIORITY APPLN. INFO.: US 1992-859927 A2 19920330
US 1993-63188 B2 19930514
WO 1994-US5374 W 19940512

AB A method is provided for using modified human cytotoxic TALL-104 cell line, which is characterized by activity against tumor cells. The method comprises treating bone marrow cells of an immunosuppressed mammalian patient with the modified TALL-104 cell line and reinjecting the treated bone marrow into the patient, as a treatment of hematol. malignancies. Also provided are effective and safe methods of use of the modified cells in the manuf. of a veterinary compn. for adoptive therapy of canine lymphoma and feline leukemias.

IC ICM A01N063-00
ICS C12N005-08; C12N005-00; C12N005-22
NCL 424093700
CC 1-6 (Pharmacology)
IT **Antitumor agents**
Antitumor agents
(B-cell lymphoma; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(acute myelogenous leukemia; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(bladder carcinoma; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(chronic myelocytic leukemia; modified TALL-104 cells to treat cancer)
IT **T cell (lymphocyte)**

(cytotoxic; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(glioblastoma; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
Antitumor agents
(hematol.; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(leukemia; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(lung carcinoma; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(lymphoma; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(mammary gland carcinoma; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(melanoma; modified TALL-104 cells to treat cancer)
IT **Adoptive immunotherapy**
Antiviral agents
Cat (Felis catus)
Cytomegalovirus
Dog (Canis familiaris)
Human immunodeficiency virus
Influenza virus
(modified TALL-104 cells to treat cancer)
IT **Interleukin 12**
Interleukin 2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(neuroblastoma; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(ovary carcinoma; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(promyelocytic leukemia; modified TALL-104 cells to treat cancer)
IT **Antitumor agents**
(prostate carcinoma; modified TALL-104 cells to treat cancer)
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:28221 HCAPLUS
DOCUMENT NUMBER: 128:70762
TITLE: Modified cytotoxic T-cell line and compositions and methods for manufacture and use thereof in adoptive cancer therapy and against virus-infected cells
INVENTOR(S): Santoli, Daniela; Rovera, Giovanni; Cesano, Alessandra
PATENT ASSIGNEE(S): Wistar Institute of Anatomy and Biology, USA
SOURCE: U.S., 32 pp., Cont.-in-part of U.S. Ser. No. 374,289.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5702702	A	19971230	US 1995-472686	19950606
US 5272082	A	19931221	US 1992-859927	19920330
CA 2162732	AA	19941124	CA 1994-2162732	19940512
ES 2171169	T3	20020901	ES 1994-917384	19940512
US 5683690	A	19971104	US 1995-374289	19950118
US 6022538	A	20000208	US 1997-847000	19970501

PRIORITY APPLN. INFO.:
US 1992-859927 A2 19920330
US 1993-63188 B2 19930514
US 1995-374289 A2 19950118
US 1995-472686 A2 19950606

AB A modified human cytotoxic T cell line is provided which is characterized by dual activity in vitro and in vivo against malignant cells and virus-infected cells. Also provided are effective and safe methods for use of the modified cells in adoptive therapy of cancer and untreatable vital diseases in MHC-mismatched recipients, and in marrow purging to achieve complete eradication of residual tumor cells from marrows of patients with leukemia and other types of cancer. Also provided are effective and safe methods for use of the cytokine stimulated, irradiated TALL-104 cells in the manuf. of a veterinary compn. for adoptive therapy of canine and feline malignancies.

IC ICM A01N063-00
ICS C12N005-00; C12N005-08; A61K031-00
NCL 424093710
CC 1-6 (Pharmacology)
Section cross-reference(s): 15

IT **Antitumor agents**
(bladder carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Interleukin 12**
Interleukin 2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell modification with; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **T cell (lymphocyte)**
(cytotoxic; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(glioblastoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
Antitumor agents
(hematol.; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(leukemia; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(lung carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Lymphocyte**
(lymphokine-activated killer cell; modified cytotoxic **T-cell** line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(lymphoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**

(malignant histiocytosis; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(mammary gland carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(melanoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Adoptive immunotherapy**
Antitumor agents
Bone marrow
Cat (Felis catus)
Cytomegalovirus
Dog (Canis familiaris)
Human immunodeficiency virus
Veterinary medicine
(modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(neuroblastoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(ovary carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(prostate carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**
(solid tumor; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

L57 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:424684 HCAPLUS
DOCUMENT NUMBER: 117:24684
TITLE: CD53 cell surface antigen and immunodiagnostic and therapeutic uses thereof and cloning and sequencing of many other cell surface antigens
INVENTOR(S): Seed, Brian; Aruffo, Alejandro; Amiot, Martine
PATENT ASSIGNEE(S): General Hospital Corp., USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9201049	A2	19920123	WO 1991-US4986	19910715
WO 9201049	A3	19930930		
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9185286	A1	19920204	AU 1991-85286	19910715
AU 658370	B2	19950413		
EP 551301	A1	19930721	EP 1991-916292	19910715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06504186	T2	19940519	JP 1991-515602	19910715

JP 2001157592 A2 20010612 JP 2000-305557 19910715
JP 2003038179 A2 20030212 JP 2002-176484 19910715
PRIORITY APPLN. INFO.: US 1990-553759 A 19900713
JP 1991-515602 A3 19910715
JP 2000-305557 A3 19910715
WO 1991-US4986 A 19910715

AB A simple and highly efficient method for cloning cDNAs from mammalian expression libraries is based on transient expression of the antigen in mammalian host cells and phys. selection of cells expressing the antigen by adhesion to an antibody-coated substrate. Novel expression vectors allowing highly efficient construction of mammalian cDNA libraries are also disclosed. The cDNAs for CD2, LFA-3, CD28, CD7, and CD53 antigens and many others were isolated, cloned, and sequenced. CD53 and its recombinant DNA, pharmaceutical compns. comprising CD53, and immunodiagnostic assay kits comprising CD53 in sol. form are claimed.

IC ICM C12N015-00
ICS C07K013-00; G01N033-569; A61K037-02

CC 15-2 (Immunochemistry)
Section cross-reference(s): 3

IT **Canis familiaris**
Goat
Horse
Rabbit
Sheep
Swine
(erythrocytes of, human CD2 antigen-expressing COS cells rosetting with)

IT **Lymphocyte**
(**B-cell**, CD20 antigen of human)

IT **Immunoglobulins**
RL: BIOL (Biological study)
(G, COS cells expressing cDNA for human CDw32 antigen response to)

IT **Immunoglobulins**
RL: BIOL (Biological study)
(G, Fc.gamma.RI receptors, macrophage-specific, cloning of cDNA for and sequence of, of human)

IT **Immunoglobulins**
RL: PRP (Properties)
(G, Fc.gamma.RII receptors, cloning of cDNA for and sequence of, of human)

IT **Immunoglobulins**
RL: BIOL (Biological study)
(G, Fc.gamma.RIIA receptors, cDNA for, nucleotide sequence of, of human)

IT **Immunoglobulins**
RL: BIOL (Biological study)
(G, Fc.gamma.RIIB receptors, cDNA for, nucleotide sequence of, of human)

IT **Immunoglobulins**
RL: BIOL (Biological study)
(G, receptors, COS cells expressing cDNA for, of human)

IT **Immunoglobulins**
RL: BIOL (Biological study)
(M, COS cells expressing cDNA for human CD7 antigen response to)

IT **Immunoglobulins**
RL: BIOL (Biological study)
(M, receptors, CD7 antigen of human in relation to)

IT **Lymphocyte**
(**T-cell**, cell surface antigens of human, cloning and expression of cDNA for)

IT **Therapeutics**
(**immuno-**, CD53 cell surface antigen for)

IT **Antibodies**
RL: BIOL (Biological study)
(monoclonal, COS cells expressing specific human cell surface antigens detection with)